Asked on Healicus
Does berberine lower blood sugar?
Answer published by a reader on . AI-generated from the sources below; general educational information, not medical advice.
Yes — berberine does lower blood sugar markers, but the effect is modest and the evidence is rated low certainty.
A meta-analysis of 20 randomised trials (n = 1,761) found that berberine reduced fasting glucose by 0.52 mmol/L, HbA1c by 4.48 mmol/mol, and a measure of insulin resistance (HOMA-IR) by 0.85, all versus placebo 3Zhao JV et al., J Nutr, 2023 — Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled TrialsMeta-analysis · J Nutr 2023Berberine is effective in improving glucose metabolism and may result in larger effects on fasting glucose in women, in people with diabetes and in Asians, but subgroup comparisons remain to be replicated given the limited number of studies.Open on pubmed.ncbi.nlm.nih.gov ↗. Effects were larger in women, people with diabetes, and Asian participants — though those subgroup comparisons rest on fewer studies. A separate trial in people with type 2 diabetes found meaningful drops in both fasting and post-meal glucose alongside improved insulin sensitivity 1Zhang Y et al., J Clin Endocrinol Metab, 2008 — Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberineRandomised trial · J Clin Endocrinol Metab 2008Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia.Open on pubmed.ncbi.nlm.nih.gov ↗.
One important caveat: these trials compared berberine to placebo, not to metformin or other diabetes medications, so we don't know how it stacks up against standard treatment. There's also a newer trial of a modified berberine compound (berberine ursodeoxycholate) showing HbA1c reductions in type 2 diabetes 5Ji L et al., JAMA Netw Open, 2025 — Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical TrialRandomised trial · JAMA Netw Open 2025In this placebo-controlled randomized clinical trial, treatment with HTD1801 resulted in significant reductions in the HbA1c level and improvements in key cardiometabolic and liver parameters. HTD1801 was safe and well tolerated. These findings are being confirmed in ongoing phase 3 studies.Open on pubmed.ncbi.nlm.nih.gov ↗, and a 2026 trial finding it reduced liver fat and visceral fat in people with obesity without diabetes 4Lei L et al., JAMA Netw Open, 2026 — Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical TrialRandomised trial · JAMA Netw Open 2026In this randomized clinical trial of diabetes-free individuals with obesity and MASLD, a 6-month berberine treatment at a daily dose of 1 g had an excellent safety profile but did not reduce VAT area or liver fat content. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05647915.Open on pubmed.ncbi.nlm.nih.gov ↗ — suggesting the molecule does more than just nudge glucose.
The catch: berberine is pharmacologically active, not a casual supplement. It inhibits liver enzymes (CYP3A4/2D6) and can interact with statins, warfarin, ciclosporin, and many cardiovascular drugs — and carries a hypoglycaemia risk if combined with insulin or sulphonylureas.
Sources
In this answer
Have a follow-up, or a question of your own? Every answer cites Cochrane, EU regulators, guideline bodies or trials in leading journals.